BCL6 and lymphoma: Though double-hit-lymphomas and triple-hit-lymphomas are clinically aggressive neoplasms with poor prognosis, no significant clinical influence of the immunohistochemical assessment of c-Myc and BCL-2/BCL-6 was found in multivariate analyses.